NASDAQ:ZSAN - Zosano Pharma Stock Price, News, & Analysis

Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."

Shares of Zosano Pharma reverse split on the morning of Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2018. An investor that had 100 shares of Zosano Pharma stock prior to the reverse split would have 5 shares after the split.

Zosano Pharma Corp (NASDAQ:ZSAN) issued its earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.78) by $0.01. View Zosano Pharma's Earnings History.

Zosano Pharma is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Zosano Pharma.

3 brokers have issued 12-month target prices for Zosano Pharma's shares. Their predictions range from $3.66 to $19.00. On average, they anticipate Zosano Pharma's stock price to reach $10.22 in the next year. This suggests a possible upside of 247.6% from the stock's current price. View Analyst Price Targets for Zosano Pharma.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zosano Pharma.

News headlines about ZSAN stock have trended positive recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zosano Pharma earned a news sentiment score of 2.6 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the next several days. View News Stories for Zosano Pharma.

Zosano Pharma saw a drop in short interest in the month of May. As of May 15th, there was short interest totalling 1,514,100 shares, a drop of 38.4% from the April 15th total of 2,459,300 shares. Based on an average trading volume of 1,220,000 shares, the short-interest ratio is currently 1.2 days. Approximately 9.1% of the shares of the company are sold short. View Zosano Pharma's Current Options Chain.

Some companies that are related to Zosano Pharma include Affimed (AFMD), Synlogic (SYBX), Ocular Therapeutix (OCUL), Kala Pharmaceuticals (KALA), Hookipa Pharma (HOOK), Aldeyra Therapeutics (ALDX), Aeglea Bio Therapeutics (AGLE), Poxel (PXXLF), Calithera Biosciences (CALA), MEI Pharma (MEIP), AcelRx Pharmaceuticals (ACRX), Mersana Therapeutics (MRSN), Chimerix (CMRX), Nature's Sunshine Products (NATR) and Acer Therapeutics (ACER).

Based on aggregate information from My MarketBeat watchlists, some companies that other Zosano Pharma investors own include Synergy Pharmaceuticals (SGYP), AEterna Zentaris (AEZS), Square (SQ), Anthera Pharmaceuticals (ANTH), Immunomedics (IMMU), Protalix Biotherapeutics (PLX), Neovasc (NVCN), Verastem (VSTM), Catalyst Pharmaceuticals (CPRX) and Evoke Pharma (EVOK).

(ZSAN) raised $47 million in an initial public offering on Tuesday, January 27th 2015. The company issued 4,300,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO.

Zosano Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include MYDA Advisors LLC (0.42%). Company insiders that own Zosano Pharma stock include Amzak Capital Management, Llc, John Peter Walker and Kenneth Greathouse. View Institutional Ownership Trends for Zosano Pharma.

ZSAN stock was purchased by a variety of institutional investors in the last quarter, including MYDA Advisors LLC. Company insiders that have bought Zosano Pharma stock in the last two years include John Peter Walker and Kenneth Greathouse. View Insider Buying and Selling for Zosano Pharma.

Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ZSAN stock can currently be purchased for approximately $2.94.

Zosano Pharma has a market capitalization of $52.11 million. The biotechnology company earns $-35,360,000.00 in net income (profit) each year or ($3.74) on an earnings per share basis. Zosano Pharma employs 53 workers across the globe.View Additional Information About Zosano Pharma.

The official website for Zosano Pharma is http://www.zosanopharma.com/.

Zosano Pharma's mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company can be reached via phone at 510-745-1200 or via email at [email protected]